Overview

Study to Assess the Efficacy and Safety of Three Doses of PT001 in Japanese Subjects With Moderate to Severe COPD

Status:
Completed
Trial end date:
2015-09-05
Target enrollment:
Participant gender:
Summary
The overall objective of this study was to assess the efficacy and safety of GP MDI relative to placebo in Japanese subjects with moderate to severe COPD. Each subject received the 4 separate study treatments, scheduled as four, 7-day, treatment periods for a total treatment duration of 28 days.
Phase:
Phase 2
Details
Lead Sponsor:
Pearl Therapeutics, Inc.
Treatments:
Glycopyrrolate